Chemomab’s Positive Trial Results Boost Investor Confidence
Company Announcements

Chemomab’s Positive Trial Results Boost Investor Confidence

Chemomab Therapeutics (CMMB) has released an update.

Chemomab Therapeutics reported promising results from its Phase 2 SPRING trial for CM-101, a potential treatment for primary sclerosing cholangitis, driving investor interest and strategic partnership discussions. The company secured $10 million in private placement funding, extending its cash runway to early 2026. Chemomab plans to advance CM-101 to a Phase 3 trial in late 2025, aiming to further capitalize on its promising pipeline.

For further insights into CMMB stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyChemomab Therapeutics reports Q3 EPS (1c) vs (2c) last year
TheFlyChemomab Therapeutics sees cash runway through beginning of 2026
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App